Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain metastases at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract 1005: TBCRC 022: Phase II Trial of Neratinib + Capecitabine for Patients (pts) with Human Epidermal Growth Factor Receptor 2 (HER2+) Breast Cancer Brain Metastases (BCBM)